Background: An accurate risk-stratification is key to optimize the benefit-to-risk ratio of palliative treatment in advanced biliary cancer. We aimed at assessing the impact of the prognostic nutritional index (PNI) on survival and treatment response in advanced biliary cancer (ABC) receiving first-line chemotherapy. Methods: Medical records of ABC treated with standard chemotherapy at the Modena Cancer Centre were retrospectively reviewed for variables deemed of potential interest, including the PNI. Univariate and multivariate analyses were performed to investigate the association between the covariates and overall survival (OS). Results: 114 ABC fulfilled the inclusion criteria and made up the training cohort. A PNI cut-off value of 36.7 was established using the receiver operating characteristic (ROC) analysis. At both the univariate and the multivariate analysis, low PNI value (<36.7) was associated with shorter OS (P =.0011), together with increased NLR (P =.0046) and ECOG >1 (P <.0001). The median OS was 5.4 vs 12.1 months in the low- vs high PNI-group. Moreover, a PNI value >36.7 resulted in a higher disease control in patients treated with gemcitabine/platinum combination (61.4% vs 34.3%). These results were validated in an independent cohort of 253 ABC. Conclusions: We demonstrated and externally validated a prognostic role for the PNI in ABC treated with first-line chemotherapy. Although the PNI turned out to be predictive in the subset of patients receiving platinum/gemcitabine combination, future prospective confirmation is needed.

The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer / Salati, M.; Filippi, R.; Vivaldi, C.; Caputo, F.; Leone, F.; Salani, F.; Cerma, K.; Aglietta, M.; Fornaro, L.; Sperti, E.; Di Maio, M.; Ortega, C.; Fenocchio, E.; Lombardi, P.; Cagnazzo, C.; Depretis, I.; Gelsomino, F.; Spallanzani, A.; Santini, D.; Silvestris, N.; Aprile, G.; Roviello, G.; Scartozzi, M.; Cascinu, S.; Casadei Gardini, A.. - In: LIVER INTERNATIONAL. - ISSN 1478-3223. - 40:3(2020), pp. 704-711. [10.1111/liv.14314]

The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer

Salati M.;Caputo F.;Cerma K.;Fornaro L.;Gelsomino F.;Spallanzani A.;Santini D.;Aprile G.;Scartozzi M.;Cascinu S.;Casadei Gardini A.
2020

Abstract

Background: An accurate risk-stratification is key to optimize the benefit-to-risk ratio of palliative treatment in advanced biliary cancer. We aimed at assessing the impact of the prognostic nutritional index (PNI) on survival and treatment response in advanced biliary cancer (ABC) receiving first-line chemotherapy. Methods: Medical records of ABC treated with standard chemotherapy at the Modena Cancer Centre were retrospectively reviewed for variables deemed of potential interest, including the PNI. Univariate and multivariate analyses were performed to investigate the association between the covariates and overall survival (OS). Results: 114 ABC fulfilled the inclusion criteria and made up the training cohort. A PNI cut-off value of 36.7 was established using the receiver operating characteristic (ROC) analysis. At both the univariate and the multivariate analysis, low PNI value (<36.7) was associated with shorter OS (P =.0011), together with increased NLR (P =.0046) and ECOG >1 (P <.0001). The median OS was 5.4 vs 12.1 months in the low- vs high PNI-group. Moreover, a PNI value >36.7 resulted in a higher disease control in patients treated with gemcitabine/platinum combination (61.4% vs 34.3%). These results were validated in an independent cohort of 253 ABC. Conclusions: We demonstrated and externally validated a prognostic role for the PNI in ABC treated with first-line chemotherapy. Although the PNI turned out to be predictive in the subset of patients receiving platinum/gemcitabine combination, future prospective confirmation is needed.
27-nov-2019
40
3
704
711
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer / Salati, M.; Filippi, R.; Vivaldi, C.; Caputo, F.; Leone, F.; Salani, F.; Cerma, K.; Aglietta, M.; Fornaro, L.; Sperti, E.; Di Maio, M.; Ortega, C.; Fenocchio, E.; Lombardi, P.; Cagnazzo, C.; Depretis, I.; Gelsomino, F.; Spallanzani, A.; Santini, D.; Silvestris, N.; Aprile, G.; Roviello, G.; Scartozzi, M.; Cascinu, S.; Casadei Gardini, A.. - In: LIVER INTERNATIONAL. - ISSN 1478-3223. - 40:3(2020), pp. 704-711. [10.1111/liv.14314]
Salati, M.; Filippi, R.; Vivaldi, C.; Caputo, F.; Leone, F.; Salani, F.; Cerma, K.; Aglietta, M.; Fornaro, L.; Sperti, E.; Di Maio, M.; Ortega, C.; Fenocchio, E.; Lombardi, P.; Cagnazzo, C.; Depretis, I.; Gelsomino, F.; Spallanzani, A.; Santini, D.; Silvestris, N.; Aprile, G.; Roviello, G.; Scartozzi, M.; Cascinu, S.; Casadei Gardini, A.
File in questo prodotto:
File Dimensione Formato  
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer.pdf

embargo fino al 24/02/2022

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 664.86 kB
Formato Adobe PDF
664.86 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1196897
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 31
social impact